{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T09:10:21Z","timestamp":1731748221920,"version":"3.28.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.urolonc.2023.11.008","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T07:23:31Z","timestamp":1705821811000},"page":"402-410","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision medicine for urothelial carcinoma: An international perspective"],"prefix":"10.1016","volume":"42","author":[{"given":"Mariane S.","family":"Fontes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel Vargas Pivato","family":"de Almeida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flavio","family":"C\u00e1rcano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo","family":"Lages","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodrigo","family":"Dienstmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.urolonc.2023.11.008_bib0001","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.1992.10.7.1066","article-title":"A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study","volume":"10","author":"Loehrer","year":"1992","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2023.11.008_bib0002","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.urolonc.2023.11.008_bib0003","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1038\/s41591-021-01579-0","article-title":"Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial","volume":"27","author":"Powles","year":"2021","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.urolonc.2023.11.008_bib0004","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/S1470-2045(17)30616-2","article-title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study","volume":"18","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"issue":"10064","key":"10.1016\/j.urolonc.2023.11.008_bib0005","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.urolonc.2023.11.008_bib0006","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.008_bib0007","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1817323","article-title":"Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma","volume":"381","author":"Loriot","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.008_bib0008","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1056\/NEJMc2106975","article-title":"Enfortumab Vedotin in Advanced Urothelial Carcinoma","volume":"385","author":"Yeon","year":"2021","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.urolonc.2023.11.008_bib0009","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7492","key":"10.1016\/j.urolonc.2023.11.008_bib0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nature12965","article-title":"Comprehensive molecular characterization of urothelial bladder carcinoma","volume":"507","year":"2014","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.008_bib0011","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.cell.2018.07.036","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"174","author":"Robertson","year":"2018","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.008_bib0012","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.008_bib0013","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2019.02.017","article-title":"The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability","volume":"75","author":"Kim","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.008_bib0014","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","article-title":"A Consensus Molecular Classification of Muscle-invasive Bladder Cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"issue":"21","key":"10.1016\/j.urolonc.2023.11.008_bib0015","doi-asserted-by":"crossref","first-page":"5500","DOI":"10.3390\/cancers13215500","article-title":"Molecular Classification of Bladder Urothelial Carcinoma Using NanoString-Based Gene Expression Analysis","volume":"13","author":"Lopez-Beltran","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.008_bib0016","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/cancers9040028","article-title":"DNA Repair Pathway Alterations in Bladder Cancer","volume":"9","author":"Mouw","year":"2017","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.urolonc.2023.11.008_bib0017","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2016.1056","article-title":"Clinical Validation of Chemotherapy Response Biomarker ERCC2 in Muscle-Invasive Urothelial Bladder Carcinoma","volume":"2","author":"Liu","year":"2016","journal-title":"JAMA Oncol"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.008_bib0018","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.euo.2020.02.003","article-title":"Defects in DNA Repair Genes Confer Improved Long-term Survival after Cisplatin-based Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer","volume":"3","author":"Miron","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.008_bib0019","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1186\/s40425-019-0619-8","article-title":"DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes","volume":"7","author":"Vidotto","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2023.11.008_bib0020","doi-asserted-by":"crossref","first-page":"866","DOI":"10.6004\/jnccn.2022.0041","article-title":"NCCN Guidelines(R) Insights: Bladder Cancer, Version 2.2022","volume":"20","author":"Flaig","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"10.1016\/j.urolonc.2023.11.008_bib0021","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.008_bib0022","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1158\/2159-8290.CD-18-0825","article-title":"Detection and Surveillance of Bladder Cancer Using Urine Tumor DNA","volume":"9","author":"Dudley","year":"2019","journal-title":"Cancer Discov"},{"issue":"8","key":"10.1016\/j.urolonc.2023.11.008_bib0023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003732","article-title":"Urine tumor DNA detection of minimal residual disease in muscle-invasive bladder cancer treated with curative-intent radical cystectomy: A cohort study","volume":"18","author":"Chauhan","year":"2021","journal-title":"PLoS Med"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.008_bib0024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12943-023-01729-7","article-title":"Letter to the Editor: clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma","volume":"22","author":"Yang","year":"2023","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.urolonc.2023.11.008_bib0025","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1038\/ng.3692","article-title":"Clonal evolution of chemotherapy-resistant urothelial carcinoma","volume":"48","author":"Faltas","year":"2016","journal-title":"Nat Genet"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.008_bib0026","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2016.01.007","article-title":"Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer","volume":"70","author":"Birkenkamp-Demtroder","year":"2016","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.008_bib0027","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3233\/BLC-170140","article-title":"Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer","volume":"4","author":"Todenhofer","year":"2018","journal-title":"Bladder Cancer"},{"issue":"7867","key":"10.1016\/j.urolonc.2023.11.008_bib0028","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.urolonc.2023.11.008_bib0029","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1038\/s41591-019-0628-7","article-title":"Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial","volume":"25","author":"Powles","year":"2019","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.008_bib0030","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1200\/JCO.2022.40.6_suppl.543","article-title":"Novel use of ctDNA to identify locally advanced and metastatic upper tract urothelial carcinoma","volume":"40","author":"Huelster","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"4","key":"10.1016\/j.urolonc.2023.11.008_bib0031","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41416-022-01776-9","article-title":"Integrating circulating-free DNA (cfDNA) analysis into clinical practice: opportunities and challenges","volume":"127","author":"Garcia-Pardo","year":"2022","journal-title":"Br J Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2023.11.008_bib0032","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1016\/S1470-2045(21)00152-2","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"issue":"10236","key":"10.1016\/j.urolonc.2023.11.008_bib0033","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/S0140-6736(20)30230-0","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.008_bib0034","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JCO.19.02105","article-title":"Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability\/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study","volume":"38","author":"Marabelle","year":"2020","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.urolonc.2023.11.008_bib0035","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","article-title":"Response Rates to Anti-PD-1 Immunotherapy in Microsatellite-Stable Solid Tumors With 10 or More Mutations per Megabase","volume":"7","author":"Valero","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.urolonc.2023.11.008_bib0036","article-title":"Harmonization of Tumor Mutational Burden Quantification and Association With Response to Immune Checkpoint Blockade in Non-Small-Cell Lung Cancer","volume":"3","author":"Vokes","year":"2019","journal-title":"JCO Precis Oncol"},{"issue":"3","key":"10.1016\/j.urolonc.2023.11.008_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.01.002","article-title":"Meta-analysis of tumor- and T cell-intrinsic mechanisms of sensitization to checkpoint inhibition","volume":"184","author":"Litchfield","year":"2021","journal-title":"Cell"},{"issue":"16 suppl","key":"10.1016\/j.urolonc.2023.11.008_bib0038","doi-asserted-by":"crossref","first-page":"3007","DOI":"10.1200\/JCO.2022.40.16_suppl.3007","article-title":"Tumor agnostic efficacy and safety of erdafitinib in patients (pts) with advanced solid tumors with prespecified fibroblast growth factor receptor alterations (FGFRalt) in RAGNAR: Interim analysis (IA) results","volume":"40","author":"Loriot","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"17 suppl","key":"10.1016\/j.urolonc.2023.11.008_bib0039","article-title":"Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt)","volume":"41","author":"Loriot","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"3","key":"10.1016\/j.urolonc.2023.11.008_bib0040","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1200\/JCO.21.02303","article-title":"FORT-1: Phase II\/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1\/3 mRNA Expression","volume":"41","author":"Sternberg","year":"2023","journal-title":"J Clin Oncol"},{"issue":"16 suppl","key":"10.1016\/j.urolonc.2023.11.008_bib0041","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1200\/JCO.2023.41.16_suppl.4577","article-title":"Evaluating the use of circulating tumor DNA (ctDNA) in patients with urothelial cancer in the context of FGFR-targeted therapy","volume":"41","author":"Sch\u00f6nlau","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"16 suppl","key":"10.1016\/j.urolonc.2023.11.008_bib0042","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1200\/JCO.2022.40.16_suppl.4568","article-title":"Landscape of fibroblast growth factor receptor (FGFR) genomic alterations (GA) in urothelial bladder cancer (UBC)","volume":"40","author":"Zerdan","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"16 suppl","key":"10.1016\/j.urolonc.2023.11.008_bib0043","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.1200\/JCO.2023.41.16_suppl.4504","article-title":"Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study","volume":"41","author":"Siefker-Radtke","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2023.11.008_bib0044","article-title":"Emerging biomarkers in urothelial carcinoma: Challenges and opportunities","volume":"25","author":"Andreatos","year":"2020","journal-title":"Cancer Treat Res Commun"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.008_bib0045","doi-asserted-by":"crossref","first-page":"TPS582","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS582","article-title":"TROPiCS-04: Study of sacituzumab govitecan (SG) in patients (pts) with locally advanced (LA) unresectable or metastatic urothelial cancer (mUC) that has progressed after prior platinum (PLT) and checkpoint inhibitor (CPI) therapy","volume":"40","author":"Vulsteke","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.urolonc.2023.11.008_bib0046","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.008_bib0047","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"10.1016\/j.urolonc.2023.11.008_bib0048","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.urolonc.2023.11.008_bib0049","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4-Positive Solid Tumors, Including Metastatic Urothelial Carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.008_bib0050","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(21)00094-2","article-title":"Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): a multicentre, single-arm, phase 2 trial","volume":"22","author":"Yu","year":"2021","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.urolonc.2023.11.008_bib0051","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance","volume":"29","author":"Klumper","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.008_bib0052","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1200\/JCO.2023.41.6_suppl.450","article-title":"Biomarkers of response to enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study","volume":"41","author":"Jindal","year":"2023","journal-title":"Journal of Clinical Oncology"},{"issue":"3-4","key":"10.1016\/j.urolonc.2023.11.008_bib0053","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"issue":"7","key":"10.1016\/j.urolonc.2023.11.008_bib0054","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1200\/JCO.2019.37.7_suppl.354","article-title":"Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I\/II study","volume":"37","author":"Tagawa","year":"2019","journal-title":"Journal of Clinical Oncology"},{"issue":"20","key":"10.1016\/j.urolonc.2023.11.008_bib0055","doi-asserted-by":"crossref","first-page":"12659","DOI":"10.3390\/ijms232012659","article-title":"Her-2 Targeted Therapy in Advanced Urothelial Cancer: From Monoclonal Antibodies to Antibody-Drug Conjugates","volume":"23","author":"Albarran","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.urolonc.2023.11.008_bib0056","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1200\/JCO.2022.40.6_suppl.438","article-title":"Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC)","volume":"40","author":"Galsky","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1016\/j.urolonc.2023.11.008_bib0057","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2022.40.16_suppl.4518","volume":"40","author":"Sheng","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1016\/j.urolonc.2023.11.008_bib0058","doi-asserted-by":"crossref","first-page":"4520","DOI":"10.1200\/JCO.2022.40.16_suppl.4520","article-title":"RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials","volume":"40","author":"Sheng","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1016\/j.urolonc.2023.11.008_bib0059","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1200\/JCO.2022.40.16_suppl.4519","article-title":"A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma","volume":"40","author":"Xu","year":"2022","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2023.11.008_bib0060","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1011885","article-title":"HER2 expression in urothelial carcinoma, a systematic literature review","volume":"12","author":"Scherrer","year":"2022","journal-title":"Front Oncol"},{"issue":"17_suppl","key":"10.1016\/j.urolonc.2023.11.008_bib0061","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA3000","article-title":"Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results","volume":"41","author":"Meric-Bernstam","year":"2023","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.urolonc.2023.11.008_bib0062","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2014.06.004","article-title":"Targeting the genetic alterations of the PI3K-AKT-mTOR pathway: its potential use in the treatment of bladder cancers","volume":"145","author":"Houede","year":"2015","journal-title":"Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.urolonc.2023.11.008_bib0063","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1158\/1078-0432.CCR-14-0947","article-title":"First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors","volume":"21","author":"Sarker","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.urolonc.2023.11.008_bib0064","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002917","article-title":"Synergistic antitumor activity of pan-PI3K inhibition and immune checkpoint blockade in bladder cancer","volume":"9","author":"Zhu","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"16","key":"10.1016\/j.urolonc.2023.11.008_bib0065","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.155899","article-title":"ARID1A-deficient bladder cancer is dependent on PI3K signaling and sensitive to EZH2 and PI3K inhibitors","volume":"7","author":"Rehman","year":"2022","journal-title":"JCI Insight"},{"issue":"5","key":"10.1016\/j.urolonc.2023.11.008_bib0066","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1002\/cncr.28477","article-title":"Double-blind, randomized, phase 2 trial of maintenance sunitinib versus placebo after response to chemotherapy in patients with advanced urothelial carcinoma","volume":"120","author":"Grivas","year":"2014","journal-title":"Cancer"},{"issue":"8","key":"10.1016\/j.urolonc.2023.11.008_bib0067","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S1470-2045(12)70294-2","article-title":"Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial","volume":"13","author":"Necchi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.urolonc.2023.11.008_bib0068","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1200\/JCO.21.00286","article-title":"Randomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)","volume":"39","author":"Rosenberg","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.urolonc.2023.11.008_bib0069","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.e16549","article-title":"Clinicopathological characterization, FGFR alteration prevalence, and outcomes of locally advanced or metastatic urothelial cancer in Latin America (LACOG 1518)","volume":"40","author":"Souza","year":"2022","journal-title":"Journal of Clinical Oncology"},{"issue":"11","key":"10.1016\/j.urolonc.2023.11.008_bib0070","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/ijc.34427","article-title":"The regulatory approvals of immune checkpoint inhibitors in China and the United States: A cross-national comparison study","volume":"152","author":"Jin","year":"2023","journal-title":"Int J Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923003605?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143923003605?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,16]],"date-time":"2024-11-16T08:33:39Z","timestamp":1731746019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143923003605"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":70,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S1078143923003605"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.008","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine for urothelial carcinoma: An international perspective","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2023.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}